Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Belluscura PLC (GB:BELL)
LSE:BELL
Holding GB:BELL?
Track your performance easily
BELL Stock Chart & Stats
Day’s Range0p - 0p
52-Week Range7.00p - 39.98p
Previous Close12p
Volume0.00
Average Volume (3M)214.59K
Market Cap
£20.21M
Enterprise Value18.88M
Total Cash (Recent Filing)$2.04M
Total Debt (Recent Filing)$302.62K
Price to Earnings (P/E)―
Beta0.80
Next Earnings
Feb 25, 2025EPS Estimate
-£0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding168,408,232
10 Day Avg. Volume287,220
30 Day Avg. Volume214,589
Standard Deviation0.25
R-Squared0.02
Alpha-0.00766
Financial Highlights & Ratios
Price to Book (P/B)80.00
Price to Sales (P/S)19.74
Price to Cash Flow (P/CF)-2.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit277.27
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Belluscura PLC News
PremiumCompany Announcements
Tekcapital Reduces Stake in Belluscura PLC
PremiumCompany Announcements
Belluscura PLC Announces Shareholding Change
PremiumCompany Announcements
Belluscura Shareholders Affirm Company Leadership
PremiumCompany Announcements
Belluscura Forecasts Strong Growth with New Oxygen TechPremiumCompany Announcements
Belluscura PLC Schedules Upcoming AGM
PremiumCompany Announcements
Belluscura Announces Total Voting Rights CountPremiumCompany Announcements
Belluscura Awards Share Options to CFO
PremiumCompany Announcements
Belluscura Announces Board Member DepartureOptions Prices
Currently, No data available
---
Ownership Overview
10.63%
Insiders
0.00% Mutual Funds
0.00% Other Institutional Investors
89.37% Public Companies and
Individual Investors
BELL FAQ
What was Belluscura PLC’s price range in the past 12 months?
Belluscura PLC lowest share price was 7.00p and its highest was 39.98p in the past 12 months.
What is Belluscura PLC’s market cap?
Currently, no data Available
When is Belluscura PLC’s upcoming earnings report date?
Belluscura PLC’s upcoming earnings report date is Feb 25, 2025 which is in 158 days.
How were Belluscura PLC’s earnings last quarter?
Belluscura PLC released its earnings results on Sep 02, 2024. The company reported -0.023p earnings per share for the quarter, the consensus estimate of -0.023p by 0p.
Is Belluscura PLC overvalued?
According to Wall Street analysts Belluscura PLC’s price is currently Overvalued.
Does Belluscura PLC pay dividends?
Belluscura PLC does not currently pay dividends.
What is Belluscura PLC’s EPS estimate?
Belluscura PLC’s EPS estimate is -£0.02.
How many shares outstanding does Belluscura PLC have?
Belluscura PLC has 168,408,230 shares outstanding.
What happened to Belluscura PLC’s price movement after its last earnings report?
Belluscura PLC reported an EPS of -0.023p in its last earnings report, expectations of -0.023p. Following the earnings report the stock price went down -18.519%.
Which hedge fund is a major shareholder of Belluscura PLC?
Currently, no hedge funds are holding shares in GB:BELL
---
Belluscura PLC Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-65.21%
12-Months-Change
Fundamentals
Return on Equity
-96.51%
Trailing 12-Months
Asset Growth
-16.73%
Trailing 12-Months
Company Description
Belluscura PLC
Belluscura PLC is a medical device company. Its first product, the X-PLO?RTM, is a lightweight FDA cleared portable oxygen concentrator designed to replace larger, metal oxygen tanks and heavier portable oxygen concentrator devices. The X-PLO?R weighs less than 1.5kg (3.25lbs) and it is the first modular portable oxygen concentrator and that it will generate more oxygen by weight than any other FDA cleared POC in its class. It either owns or exclusively licenses a total of 26 patents and applications relating to oxygen enrichment devices and treatments.
---
Technical Analysis
RUA Life Sciences
―
Tissue Regenix
―
HemoGenyx Pharmaceuticals Plc
―
EKF Diagnostics Holdings
―
---